While the strategic review process is ongoing, the Company intends to continue to pursue its core strategic objectives so as to maintain and enhance the value of its current business and operations, including the development and launch of the iSTRYM TM product. The Special Committee is being chaired by Jason Pamer, includes Larissa Chaikowsky, Robert Hill and Philip Tapley, and has appointed Canaccord Genuity Corp. as its financial advisor to support the Special Committee in the strategic review process. I look forward to engaging in this process with the Special Committee while my team pursues our ambitious plan, supported by our strong financial position,' said MINDCURE's President and CEO Kelsey Ramsden. 'I am proud of our team and track record of delivering on milestones with focus and drive. However, the Board believes that given the current state of capital markets and the evolving landscape for our industry, a broad review of strategic alternatives is entirely appropriate and in the best interest of the Company,' said the Chair of MINDCURE's Board of Directors, Philip Tapley. As we recently reported, the Company is in a strong financial position with cash and equivalents of $13.4M and a cash runway of a minimum 12 months as at November 30, 2021.

'The Board continues to support the Company's current strategic priorities.

The Special Committee's strategic review process will encompass an evaluation of the Company's current strategic direction, operations, market valuation and capital structure and will consider appropriate alternatives for the Company which may include one or more of the following: continuation as a standalone public company, strategic investor investment, acquisition by or a merger with an industry partner that may involve all or part of our business or assets and any other strategic alternatives that may be identified during our strategic review. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ('MINDCURE' or the 'Company'), a leader in advanced proprietary technology for mental health care and research in psychedelics, announced today its Board of Directors has formed a special committee (the 'Special Committee') of independent directors to initiate a review process to explore, review and evaluate a broad range of strategic alternatives. 10, 2022 /PRNewswire/ - Mind Cure Health Inc.

Novamind 5 review